Search
for
Sort by
Research 31–60 of 1000+
- First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
- Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- 2-Substituted 4-(Thio)chromenone 6-<i>O</i>-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata
- A Natural Inhibitor, 1′S-1′-Acetoxychavicol Acetate, Against Testosterone-Induced Alopecia via NADPH Oxidase Regulation
- Novel inhibitors of 5α-reductase
- Platelet-Rich Plasma Contains High Concentrations of DKK1, A Potent Inhibitor of Wnt Signaling that Limits Bone Regeneration and Hair Growth
- Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- ISID1373 - Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- 1373 Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves’ ophthalmopathy
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Survey of pediatric dermatologist views on treatment for alopecia areata
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- Modulation der Hitzesensitivität im Prostatakarzinom in vitro: Der Einfluss der Androgenachse
- Tregs: Where We Are and What Comes Next?
- Update on hidradenitis suppurativa: connecting the tracts
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Androgens and Parkinson’s disease: the role in humans and in experiment